Current studies have shown that sarsasapogenin significantly inhibits key enzymes involved in AD pathogenesis, namely AChE, BuChE, BACE1, and MAO-B77,78, in a concentration-dependent manner. Here, BACE1 is linked to Alzheimer disease.